JDRF T1D Fund — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesCerity Partners VenturesColorcon VenturesHikma VenturesSanofi Ventures
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsadMare BioInnovationsAmorChemGenesys CapitalNew Enterprise Associates (NEA)Tarnagulla VenturesAmgen Ventures+2 more
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Torben Straight Nissen(Chief Executive Officer)inAnthony Coyle(President, Research and Development)inRobert Andtbacka(Chief Medical Officer)inJohn Delyani(Chief Business Officer)inJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in
Co-investorsFlagship PioneeringSoftBank Vision Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.














